Ionis Pharmaceuticals (IONS) Fundamental Analysis: Revenue, Earnings & Valuation

2.76 / 10

Underperform

Fundamental analysis rates IONS as Underperform with a 2.8/10 score. Inventory and receivables turnover are decent, and cost‑of‑sales ratio is low, but income‑tax ratio is negative, revenue growth shows volatility, and overall profitability appears weak.

Analysis Checks(7/10)

Revenue-MV

Value-1.79

Score1/3

Weight20.88%

1M Return5.06%

Total operating revenue (YoY growth rate %)

Value33.83

Score1/3

Weight-4.80%

1M Return-1.40%

Inventory turnover ratio

Value1.41

Score2/3

Weight-2.48%

1M Return-0.66%

Accounts receivable turnover ratio

Value23.61

Score2/3

Weight-2.22%

1M Return-0.65%

PB-ROE

Value2.50

Score2/3

Weight44.16%

1M Return8.98%

Income tax / Total profit (%)

Value-0.47

Score1/3

Weight-2.03%

1M Return-0.59%

Fixed assets turnover ratio

Value3.06

Score2/3

Weight-3.53%

1M Return-1.01%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-2.50%

1M Return-0.73%

Cost of sales ratio (%)

Value1.69

Score3/3

Weight3.11%

1M Return0.79%

Asset-MV

Value-0.55

Score2/3

Weight49.41%

1M Return9.91%

Is IONS undervalued or overvalued?

IONS scores 2.76/10 on fundamentals and holds a Premium valuation at present. Backed by its -70.80% ROE, -40.41% net margin, -30.18 P/E ratio, 23.53 P/B ratio, and 21.71% earnings growth, these metrics solidify its Underperform investment rating.